Aurobindo Pharma expands in Europe
- Details
- Category: Business
Aurobindo Pharma announced that it has recently concluded a strategic deal, for acquisition of Intellectual Property & Marketing Authorizations, with TAD Italy, a generic company registered in Italy. This acquisition will give Aurobindo an access to more than 70 ready to market products which will fast track Aurobindo's entry into the Italian generic market.
GSK charitable support valued at £282 million in 2007
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline reported its 2007 global giving to charitable initiatives totalled £282 million, equivalent to almost 4% of pre-tax profits for the company (with the FTSE 100 average around 1%). Donations of albendazole treatments for the company's flagship programme to eliminate Lymphatic Filariasis (commonly known as elephantiasis) were valued at £14 million, bringing the total number of treatments given since GSK made its commitment 10 years ago to almost 750 million.
Federal Court of Appeal in Canada Upholds Lipitor Enantiomer Patent
- Details
- Category: Pfizer
Pfizer Inc said today that the Federal Court of Appeal of Canada has reversed a lower court ruling that held that Pfizer's enantiomer patent could not block generic manufacturer Ranbaxy Laboratories Limited from obtaining approval for a competitor product to Lipitor. The appellate court issued an order prohibiting regulatory approval of Ranbaxy's product in Canada until Pfizer's enantiomer (calcium salt) patent - Canadian Patent No. 2,021,546 - expires in July 2010.
Zevalin® Receives Positive CHMP Opinion in Europe for First-Line Consolidation Treatment
- Details
- Category: Bayer
Bayer Schering Pharma AG has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending Zevalin® ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma (FL) in Europe.
Genzyme Withdraws Bioenvision's European Filing of Evoltra® in Elderly AML Patients
- Details
- Category: Genzyme
Genzyme Corp. (Nasdaq: GENZ) announced the withdrawal of the European application to extend the Evoltra® (clofarabine) product label to include the treatment of elderly patients with acute myeloid leukemia (AML). This application and the data on which it was based were filed by Bioenvision, Ltd. before the company was acquired by Genzyme last year.
GSK statement on MHRA investigation
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) notes the conclusions announced by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding its investigation into disclosure of paediatric trial data for the anti-depressant medicine Seroxat (paroxetine).
First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
- Details
- Category: Abbott
Data published in The Lancet from ABSORB, the world's first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (retreatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year.
More Pharma News ...
- Trial Date Set For SEROQUEL® Patent Litigation
- Femara® helps protect against return of breast cancer
- Nycomed intends to move chemical production to Indian joint venture
- Baxter and its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs
- A successful 2007 paves the way for future of Nycomed
- Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
- Pfizer Wins Challenge to Two Main U.S. Patents for Celebrex